Abstract: Embodiments of the invention are directed to methods of determining the prognosis of a breast cancer patient by evaluating the activity of the glucocorticoid receptor in tumor cells. Other embodiment include methods of treating breast cancer cells, particularly, chemo-resistant cells, with a glucocorticoid receptor antagonist and an anticancer agent or compound.

Abstract: In aspects, the present disclosure provides a method of treating or preventing a uterine leiomyosarcoma in a female mammal, the method comprising, consisting essentially of, or consisting of administering to the female mammal an effective amount of an inhibitor of bromodomain-containing protein 9 (BRD9).

Abstract: A method and system that harnesses extremely weak Kerr-type nonlinearities in a single driven cavity to deterministically generate single photon Fock states, and more general photon-blockaded states are disclosed. The disclosed scheme is effective even for nonlinearities that are much smaller than photonic loss in the cavity. The disclosed scheme generates photon-blockade states that are non-Gaussian, exhibit a sharp cut-off in their photon number distribution, and can be arbitrarily close to, for example, a single-photon Fock state. This scheme relies only standard linear and parametric drives, and are hence compatible with a variety of different photonic platforms.

Abstract: Certain embodiments are directed to compositions and methods for capture of elements in physical proximity. In certain aspects the methods comprise (a) contacting a target with a functionalized scaffold or capture agent that comprises activatable cross-linking moieties to form a target/scaffold mixture; (b) exposing the target/scaffold mixture to an activator to activate the cross-linking moieties of the dendrimer and form a cross-linked target/scaffold complex; (c) isolating the target/scaffold complexes; and (d) identify portions of the target or targets that are cross linked with the scaffold.

Abstract: Provided herein are peptide-based therapeutics that target FOXP3 and methods of use thereof to decrease the immuno-suppressive effects of Tregs and inhibit immune dysregulation, while sparring inhibition of activated cytotoxic T cells, for example, in the context of anti-tumor immune responses, autoimmunity, inflammatory conditions, etc.

Abstract: A method of determining a molecular structure of a compound includes obtaining a known molecular formula of the compound based on at least one of an observed spectrum and stoichiometric calculations. Edges that meet per-vertex constraints of the molecular formula are determined, and a plurality of candidate structures is generated based on the determined edges. The plurality of candidate structures are evaluated, and one candidate structure of the plurality of candidate structures is determined as the molecular structure of the compound based on the evaluation of the plurality of candidate structures.

Abstract: Functionalized nanoparticles for inhibiting or preventing pathogen infections (e.g., viral or bacterial infections, such as coronavirus infections) are described. The nanoparticles comprise a biodegradable polymer core and a lipid coating layer that is functionalized with a pathogen-binding receptor (e.g., an angiotensin-converting enzyme 2 (ACE2) receptor protein) and/or a pathogen-binding antibody or an antigen-binding fragment thereof (e.g., a virus-binding antibody or an antigen-binding fragment thereof). The nanoparticles are further functionalized by a phagocyte-specific ligand, e.g., a phosphatidylserine-containing lipid included in the lipid coating layer, to promote clearance of nanoparticle-bound pathogen. Methods of using the nanoparticles to treat or prevent pathogen infections (e.g., coronavirus infections) are also described.

Abstract: Provided herein are polymer-stabilized CaP nanoparticle formulations and related methods of manufacture. In certain embodiments, the methods reliably and selectively form nanoparticles with homogenous size, charge, and morphology. The CaP nanoparticles include calcium ions and phosphate ions with an ionic polymer, thereby forming stable hybrid nanoparticles. The CaP nanoparticle formulations include powders, suspensions and injectable pastes. According to various embodiments, the polymer-stabilized CaP nanoparticles may be polycation-stabilized (CaP/polymer(+) nanoparticles) or polyanion-stabilized (CaP/polymer(?) nanoparticles). The CaP/polymer nanoparticles can be freeze-dried and stored for months with no loss of properties or changes to their morphology.

Abstract: The disclosure is directed to devices, systems, and methods for performing quantum state-mediated microwave-to-optical energy conversion. Such quantum state-mediated energy conversion may be achieved via coherent interactions between an optical excitation and microwave electric field mediated by various quantum states in a defect embedded in a crystalline lattice. Such energy conversion enables coherent electro-optical modulation of optical emission from the defect, microwave-optical transduction, optical detection of microwave, and optical frequency mixing in the optical emission from the defect. The optical emission from the defect maintains and carries quantum coherence in the defect. Such devices and methods may be applied in quantum information processing systems.

Abstract: The current application describes various compositions and methods for the production of FN3-based binding proteins with improved stability properties. Aspects of the disclosure relate to polypeptides comprising a variant fibronectin type III (FN3) domain from Sulfolobus tokodaii or Pyrococcus horikoshii comprising one or more amino acid substitutions or insertions in a loop region of FN3, in a non-loop region of FN3, or in both.

Abstract: This invention discloses methods and compositions for the treatment of demyelinating disorders. Specifically, the invention relates to the use guanabenz or guanabenz derivative for treating demyelinating disorders.

Abstract: Provided is a method of treating a disorder mediated by claudin-2 and/or claudin-15, particularly an intestinal disorder, such as colitis or enteritis. The method comprises administering to the subject an effective amount of a compound of formula (I), formula (II), or otherwise as described herein or a pharmaceutically acceptable salt thereof. In another aspect, also provided are compounds of formula (Ia) and pharmaceutically acceptable salts thereof.

Abstract: A radiology workstation (24) includes at least one display component (30, 32); at least one user input device (28); and at least one microprocessor (26, 34) programmed to generate a contextual ranking of clinical codes for a context received via the at least one user input device (28) and to display information pertaining to the contextual ranking on the display component (30, 32) of the radiology workstation (24). The contextual ranking is computed by the microprocessor from (i) statistics of occurrences of the clinical codes in radiology reports contained in a radiology reports database (10) and satisfying the context and (ii) statistics of the clinical codes in problem lists contained in a problem lists database and satisfying the context.

Abstract: The present disclosure is directed to methods and/or uses of oligonucleotide conjugates for assays and flow cytometry detections and related systems and/or kits. Certain methods are directed to a method for detecting one or more biological targets of a sample in a detection assay, comprising: providing a molecular probe, comprising a binding moiety and an oligonucleotide sequence, to a sample comprising one or more biological targets; binding the one or more biological targets with the binding moiety; providing a detectable component to the sample, wherein the detectable component comprises a signal generating moiety conjugated to an oligonucleotide sequence complementary to the oligonucleotide sequence of the molecular probe; hydridizing the oligonucleotide sequence of the target-bound molecular probe to the detectable component; and detecting a signal generated from the hydridized detectable component. Various other embodiments, applications etc. are disclosed herein.

Abstract: Described herein are novel ?- and ?-propargyl carboxylic acids and esters. The novel compositions are antagonists of CSE and may be used to modulate of the activity of the carotid body, therefore providing therapeutic benefits for sleep-related breathing disorders and related conditions.

Abstract: Disclosed herein is a class of molecules termed remodilins that are effective in treating asthma, pulmonary fibrosis, and associated disorders. The molecules ameliorate asthma and pulmonary fibrosis symptoms by various mechanisms, including inhibiting airway smooth muscle contractile protein accumulation, reducing airway constrictor hyperresponsiveness, inhibiting bronchial fibroblast transformation into myofibroblasts, and/or treating or preventing airway or pulmonary fibrosis.

Abstract: Embodiments of the invention are directed to methods of determining the prognosis of a breast cancer patient by evaluating the activity of the glucocorticoid receptor in tumor cells. Other embodiment include methods of treating breast cancer cells, particularly, chemo-resistant cells, with a glucocorticoid receptor antagonist and an anticancer agent or compound.

Abstract: The present disclosure provides macrocyclic and macrobicyclic peptides with secondary structures that are stabilized over the corresponding non-cyclic peptides. The macrocyclic and macrobicyclic peptides are formed from peptides with adduct-forming, complementary reactive side chain moieties.

Abstract: The current disclosure relates to methods for treating ovarian cancer based on specific antigen expression of the cancer. Furthermore, the expressed antigen may be used in immunotherapeutic methods for treatment of the ovarian cancer. Aspects of the disclosure relate to immunotherapies targeting CT45 polypeptides, methods for treating ovarian cancer based on CT45 expression, and kits for detecting CT45 polypeptides and nucleotides.

Abstract: A method for quantum spin amplification includes spin-polarizing an ensemble of quantum spins in an initial spin state to generate a transversely-polarized sensing spin state. The quantum spins identically have an upper energy state and a lower energy state. The sensing spin state accumulates a phase shift that transforms the sensing spin state into a phase-accumulated spin state having first and second transverse polarization components. The phase-accumulated spin state is transformed into an intermediate spin state by rotating the first transverse polarization component into a longitudinal polarization component of the intermediate spin state. The ensemble is then coupled to an auxiliary mode, during which the intermediate spin state evolves such that the second transverse polarization component is amplified into an amplified transverse polarization. This amplified transverse polarization is then measured.